EyePoint Pharmaceuticals Presents Positive Data of Yutiq and Dexycu in Four Poster Sessions at AAO 2020

EyePoint Pharmaceuticals announced that positive data for Yutiq and Dexycu were featured in four presentations at the recent American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting.

Data presented included:

• Statistically significant efficacy results from the second phase 3 trial of Yutiq.
• Data from a multicenter retrospective study of real-world usage of Dexycu which demonstrated significant inflammatory reduction post-cataract surgery.
• New data from an investigator-initiated open-label study comparing a drug treatment regimen of Dexycu with Prolensa to a full postoperative eye drop treatment regimen which showed superior effects on inflammation, pain, visual acuity and patient preference in favor of the Dexycu arm. Importantly, patient out of pocket costs were 3.5 higher in the full postoperative eye drops treatment regimen.

“The positive and durable results of both Yutiq and Dexycu presented at AAO continue to provide strong support to their product profiles and long-term advantages compared to standard of care treatments,” Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals, said in a company news release. “Our dedicated Yutiq salesforce and combined Dexycu sales team with ImprimisRx are actively engaging treating physicians across the U.S. in order to expand the reach of our products for patients in need.”

Summaries of the AAO presentations are as follows:

Paper Presentation

Title: FAi Insert Treatment for Noninfectious Posterior Uveitis: Three-Year Results of a Confirmatory Trial

Presenter: Glenn J. Jaffe, M.D., Robert Machemer M. D. Distinguished Professor of Ophthalmology, Duke University School of Medicine

Data presented at AAO continues to show consistent efficacy and durability of Yutiq in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Results from the second double-masked, randomized phase 3 trial of Yutiq were presented from 153 patients with chronic non-infectious uveitis affecting the posterior segment of the eye, with 101 eyes treated with Yutiq and 52 eyes receiving sham injections. At 36 months, the recurrence rate in Yutiq-treated eyes was significantly lower than in sham-treated eyes (46.5% vs. 75.0%, respectively; p=0.001). Visual acuity gains or losses of 3 lines or more were both similar between treatment groups. Considerably fewer Yutiq-treated eyes (8.9%) needed adjunctive intraocular/periocular injections for uveitic inflammation compared to sham-treated eyes (51.9%). 31.7% of Yutiq-treated patients were given adjunctive systemic steroid or immunosuppressant compared to 32.7% of sham-treated eyes. Macular edema was resolved in 75.8% of Yutiq treated eyes and 53.8% of sham treated eyes that had edema recorded at baseline. Mean intraocular pressure (IOP) at 36 months was 14.8 mmHg and 13.4 mmHg in the Yutiq treated eyes and sham treated eyes, respectively. Intraocular pressure-lowering drops were used in 74.3% of Yutiq-treated eyes and 73.1% of sham-treated eyes.

Poster Presentations

Title: The D3 Study: Drug Delivery vs. Drops—A Prospective Clinical Study Evaluating Dexycu vs. Prednisolone Acetate 1% in Controlling Postoperative Pain and Inflammation in Patients Undergoing Sequential Cataract Surgery

Presenter: John A. Hovanesian, M.D., Specialist in Cataract, Refractive, Cornea and Pterygium Surgery, Harvard Eye Associates

Data from an investigator-initiated study showed patients significantly preferred a regimen of drug delivery of Dexycu and Prolensa, a commonly used non-steroidal anti-inflammatory, compared to a full post-operative eye drop regimen. Pain was significantly reduced in the Dexycu and Prolensa treatment group compared to a full post-operative eye drop treatment regimen. Ocular inflammation scores were significantly higher for the full post-operative eye drop treatment regimen compared to the Dexycu and Prolensa regimen. The proportion of patients with uncorrected vision of 20/20 was significantly higher at all time points in patients in the Dexycu and Prolensa regimen compared to the full postoperative eye drop treatment regimen. Data also showed out of pocket costs were 3.5 times higher for the full post-operative eye drop treatment regimen compared to Dexycu and Prolensa regimen.

Results presented from the post-approval, open-label, randomized, prospective, contralateral eye study consisted of 30 patients (60 eyes) undergoing routine cataract surgery. Patients were randomized to receive Dexycu intracameral, Moxifloxacin Intracameral, Prolensa or control (Prednisolone drops, Moxifloxacin drops and Prolensa) in the first eye and the alternative regimen in the second eye.

Title: Dexamethasone Intraocular Suspension 9% After Cataract Surgery: Data from a Retrospective Study

Presenter: Robert J. Weinstock, MD, Director of Cataract and Refractive Surgery, The Eye Institute of West Florida and the Weinstock Laser Eye Center

Results from the real-world multicenter retrospective study demonstrated the anti-inflammatory efficacy and tolerability of Dexycu that mirror the results seen in the controlled Phase 3 clinical trials.

Results were presented from 641 eyes of 527 patients treated with Dexycu. The proportion of eyes with complete anterior chamber cell clearing (cell score=0), a measurement of inflammation, was 40.0%, 65.1%, 85.0% and 89.7% at postoperative day 1, 8, 14 and 30, respectively. The proportion of patients with no anterior chamber flare (flare score=0), another measurement of inflammation, was 78.5%, 93.3%, 97.8% and 97.2% at postoperative day 1, 8, 14 and 30, respectively. Targeted best corrected visual acuity was achieved in 97% of eyes. Mean intraocular pressure at postoperative day 1 was 18.6 mmHg, with levels decreasing through to postoperative day 30. Each time point of data in the real-world study reflects patient chart data and frequency of measurement by participating physicians.

Title: Outcomes with Dexamethasone Intraocular Suspension 9% and Concomitant Postoperative Anti-inflammatory Medications

Presenter: Cynthia Matossian, M.D., Founder and Chief Executive Officer, Matossian Eye Associates

Real-world data of Dexycu showed strong anti-inflammatory efficacy with and without additional topical anti-inflammatory treatment. These results also showed early and sustained anterior chamber cell and flare clearing following Dexycu treatment.

Results from the multicenter retrospective study were presented from 641 eyes of 527 patients treated with Dexycu. The proportion of eyes with complete anterior chamber cell clearing (cell score=0) treated with Dexycu and a topical nonsteroidal anti-inflammatory drug (but no topical steroid) was 58.7%, 67.9%, 84.3% and 92.6% at postoperative day 1, 8, 14 and 30, respectively. This compares to anterior chamber cell clearing in eyes treated with Dexycu only of 23.9%, 69.0%, 93.8%, and 94.1% at postoperative day 1, 8, 14 and 30, respectively. The proportion of eyes with no anterior chamber flare (flare score=0) treated with Dexycu and a nonsteroidal anti-inflammatory drug was 78.9%, 93.8, 98.5% and 99.3% at postoperative day 1, 8, 14 and 30, respectively. This compares to an anterior chamber flare score in eyes treated with Dexycu only of 78.8%, 98.4%, 100.0% and 98.4% at postoperative day 1, 8, 14 and 30, respectively. Data at each timepoint in this real-world study reflects patient chart data and frequency of measurement by participating physicians.